13F filer · CIK 1773195
Affinity Asset Advisors, LLC
NEW YORK, NY · filing since Q4 2020 · last filing Aug 13, 2026
Reported value
$2.2B
+$276.2M vs prior
Positions
113
New / sold out
26 / 18
Added / reduced
33 / 30
Turnover
24.4%
buys $505.3M · sells $596.1M
Top-10 weight
39.4%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | FIRST TRACKS BIOTHERAPEUTICS | +2,032,012 | – | +$40.9M |
| New | MODERNA INCPUT | +500,000 | – | +$35.0M |
| Added | ROIVANT SCIENCES LTD | +950,000 | +33.9% | +$33.6M |
| New | ARK ETF TRCALL | +750,000 | – | +$31.5M |
| Added | AVALO THERAPEUTICS INC | +1,559,160 | +116.3% | +$28.8M |
| Added | REVOLUTION MEDICINES INC | +150,000 | +150.0% | +$28.1M |
| New | LLYELI LILLY & COCALL | +20,000 | – | +$24.0M |
| Added | INSMED INC | +170,000 | +35.4% | +$18.1M |
| Added | BELITE BIO INC | +100,000 | +153.8% | +$15.4M |
| New | IDEAYA BIOSCIENCES INC | +400,000 | – | +$14.9M |
49 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | SPYSTATE STR SPDR S&P 500 ETF TPUT | -200,000 | -100.0% | $-130.1M |
| Sold out | CENTESSA PHARMACEUTICALS PLC | -1,400,000 | -100.0% | $-55.6M |
| Sold out | ARCELLX INC | -362,764 | -100.0% | $-41.7M |
| Reduced | APOGEE THERAPEUTICS INC | -297,926 | -23.2% | $-39.5M |
| Reduced | TEVA PHARMACEUTICAL INDS LTD | -1,026,000 | -73.3% | $-34.8M |
| Sold out | TERNS PHARMACEUTICALS INC | -562,631 | -100.0% | $-29.7M |
| Reduced | MODERNA INCCALL | -325,000 | -40.6% | $-22.8M |
| Sold out | ASCENDIS PHARMA A/S | -95,000 | -100.0% | $-21.7M |
| Sold out | BRISTOL-MYERS SQUIBB COCALL | -300,000 | -100.0% | $-18.2M |
| Reduced | CYTOKINETICS INC | -150,483 | -21.5% | $-12.8M |
38 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | ROIVANT SCIENCES LTDSHS | 3,750,000 | $132.7M | 6.00% |
| 2 | APOGEE THERAPEUTICS INCCOM | 987,000 | $131.0M | 5.92% |
| 3 | SPYRE THERAPEUTICS INCCOM NEW | 1,279,134 | $113.6M | 5.13% |
| 4 | XENON PHARMACEUTICALS INCCOM | 1,595,000 | $96.3M | 4.35% |
| 5 | ERASCA INCCOM | 5,250,000 | $96.2M | 4.35% |
| 6 | INSMED INCCOM PAR $.01 | 650,000 | $69.3M | 3.13% |
| 7 | PRAXIS PRECISION MEDICINES ICOM NEW | 185,000 | $61.9M | 2.80% |
| 8 | ALKERMES PLCSHS | 1,125,000 | $58.9M | 2.66% |
| 9 | ORUKA THERAPEUTICS INCCOM | 590,000 | $56.2M | 2.54% |
| 10 | ANAPTYSBIO INCCOM | 826,109 | $55.8M | 2.52% |
103 more rows. Subscribe for $29/month to see every row, download the data and use the API.